Tumor Necrosis Factor-Neuropeptide Y Cross Talk Regulates Inflammation, Epithelial Barrier Functions, and Colonic Motility

Bindu Chandrasekharan, Emory University
Sabrina Jeppsson, Emory University
Stefan Pienkowski, Emory University
Denise D. Belsham, University of Toronto
Shanthi V. Sitaraman, Emory University
Didier Merlin, Georgia State University
Efi Kokkotou, Harvard University
Asma Nusrat, Emory University
Malu Tansey, Emory University
Shanthi Srinivasan, Emory University

Journal Title: Inflammatory Bowel Diseases
Volume: Volume 19, Number 12
Publisher: Oxford University Press (OUP): Policy B - Oxford Open Option B - CC-BY | 2013-11-01, Pages 2535-2546
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1097/01.MIB.0000437042.59208.9f
Permanent URL: https://pid.emory.edu/ark:/25593/txnw7

Final published version:
http://dx.doi.org/10.1097/01.MIB.0000437042.59208.9f

Copyright information:
© 2013 Crohn's & Colitis Foundation of America, Inc.

Accessed December 15, 2019 11:05 PM EST
Tumor necrosis factor (TNF)-neuropeptide Y (NPY) crosstalk regulates inflammation, epithelial barrier functions and colonic motility

Bindu Chandrasekharan, PhD
Sabrina Jeppsson, BA
Stefan Pienkowski, BA
Denise D Belsham, PhD
Shanthi V. Sitaraman, MD, PhD
Didier Merlin, PhD
Efi Kokkotou, MD, PhD
Asma Nusrat, MD
Malu G. Tansey, PhD
Shanthi Srinivasan, MD

Division of Digestive Diseases, Department of Medicine, Emory University, 615 Michael Street, Atlanta, GA-30322
Department of Physiology, University of Toronto, Ontario, Canada-M5S 1A8
Department of Biology, Center for Diagnostics and Therapeutics, Suite 790 Petit Science Center, Georgia State University, Atlanta, GA-30303
Veterans Affairs Medical Center, Decatur, GA-30033, US
Division of Gastroenterology, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA-02215
Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA-30322
Department of Physiology, Emory University, Atlanta, GA-30322

Abstract

Background—Neuro-immune interactions play a significant role in regulating the severity of inflammation. Our previous work demonstrated that neuropeptide Y (NPY) is up regulated in the enteric nervous system (ENS) during murine colitis, and that NPY knockout mice exhibit reduced inflammation. Here we investigated if NPY expression during inflammation is induced by tumor necrosis factor (TNF), the main pro-inflammatory cytokine.

Methods—Utilizing primary enteric neurons and colon explant cultures from WT and NPY knockout (NPY<sup>−/−</sup>) mice, we determined if NPY knockdown modulates TNF release and epithelial permeability. Further we assessed if NPY expression is inducible by TNF in enteric neuronal cells and mouse model of experimental colitis, utilizing the TNF inhibitors-etanercept (blocks transmembrane and soluble TNF) and XPro1595 (blocks soluble TNF only).

Results—We found that enteric neurons express TNF receptors (TNFR1 and R2). Primary enteric neurons from NPY<sup>−/−</sup> mice produced less TNF compared to WT. Further, TNF activated NPY promoter in enteric neurons via phospho-c-jun. NPY<sup>−/−</sup> mice had decreased intestinal...
permeability. In vitro, NPY increased epithelial permeability via phosphatidyl inositol-3-kinase (PI3-K)-induced pore-forming claudin-2. TNF inhibitors attenuated NPY expression in vitro and in vivo. TNF-inhibitor-treated colitic mice exhibited reduced NPY expression and inflammation, reduced oxidative stress, enhanced neuronal survival and improved colonic motility. XPro1595 had more protective effects on neuronal survival and motility compared to etanercept.

Conclusions—We demonstrate a novel TNF-NPY cross talk that modulates inflammation, barrier functions and colonic motility during inflammation. It is also suggested that selective blocking of soluble TNF maybe a better therapeutic option than using anti-TNF antibodies.

Keywords
NPY; TNF; enteric neurons; experimental colitis; barrier functions; colonic motility

Introduction

Neuro-immune cross talk has been identified to play a critical role in the pathogenesis of inflammatory diseases (1–3). Neuropeptide Y (NPY) is a 36 amino-acid peptide abundantly produced in the murine enteric neurons (4). NPY is implicated in inflammatory diseases (5, 6) due to its ability to regulate immune responses (7). Previously we have demonstrated that colonic NPY is upregulated during murine experimental colitis and that NPY knockout mice (NPY<sup>−/−</sup>) are protected against dextran sodium sulfate (DSS) and Salmonella typhimurium models of colitis (8). However, the mechanisms that trigger NPY expression in the enteric nervous system (ENS) during inflammation are poorly understood. The pro-inflammatory cytokine, tumor necrosis factor (TNF) plays a central role in the pathogenesis of inflammatory bowel disease (IBD). Anti-TNF antibodies (infliximab, etanercept) are the popular drugs in IBD (9) to curb the increased TNF levels during inflammation (10). Increased TNF levels has been demonstrated to increase epithelial permeability (11), induce neuropathic pain (12) and colonic motility dysfunctions (13, 14). In the present study we investigated if TNF induces NPY expression during inflammation in the ENS, and whether NPY-TNF interactions can regulate inflammation, epithelial permeability and colonic motility.

To elucidate this interaction we utilized two TNF inhibitors- etanercept (a recombinant fusion protein) that blocks both transmembrane (26 kd TNF precursor) and soluble forms of TNF (17 kd); and XPro1595 (dominant negative inhibitor of TNF) that blocks only the soluble form. Despite their popular use, the effects of TNF blockers on enteric neurons have not been investigated. We determined if NPY expression is regulated by TNF in enteric neurons in vitro and in a mouse model of colitis utilizing the TNF inhibitors.

We identified that enteric neurons express TNF receptors (TNFR1 and TNFR2), and hence are direct targets of anti-TNF drugs. TNF inhibitors attenuated NPY expression in enteric neurons, and TNF activated neuronal NPY promoter. Enteric neurons from NPY<sup>−/−</sup> mice secreted less TNF compared to WT mice, and NPY<sup>−/−</sup> mice had decreased intestinal permeability. We observed that NPY directly increased epithelial permeability via phosphatidyl inositol-3-kinase (PI3-K)-induced up regulation of claudin-2. In colitic mice, TNF inhibitors reduced NPY expression in enteric neurons, reduced oxidative stress and...
neuronal apoptosis and improved colonic motility. Selective blocking of soluble TNF by XPro1595 in mice proved more beneficial in attenuating oxidative stress, and improving neuronal survival and colonic motility.

**Materials and Methods**

**Animals**

All animal protocols were approved by the Emory University Institutional Animal Care and Use Committee (IACUC). Mice (Stock No.002448, 129 S3/SvImJ) were obtained from Jackson Laboratory (Bar Harbor, Maine, US).

**Induction of colitis**

Colitis was induced as per the documented protocols (15) in mice by administering 3% (w/v) dextran sodium sulfate (DSS, MP Biomedicals, CA) in drinking water for a week. In addition to receiving DSS, two groups of mice also received an intraperitoneal injection of one of the TNF inhibitors etanercept or XPro1595 (both from Xencor, Monrovia, CA) @ 10 mg/kg body weight) on days 1, 4 and 7. The mice were euthanized on day 8. The experimental design is given in Figure 1A. The distal colon was collected in liquid nitrogen to be used later for real-time PCR and Western blotting or cryo fixed (OCT) or paraffin embedded for hematoxylin-eosin staining or immunostaining.

**Human study**

The study was approved by Emory University Institutional Review Board Committee and Beth Israel Deaconess Medical Center (Boston, MA). Pre-operative medical records were reviewed for documented history of IBD. Colonic biopsies were obtained during endoscopy from healthy controls or patients with IBD (after informed consent) at Beth Israel Deaconess Medical Center, Emory University hospital, Atlanta, GA and the Atlanta VA Medical Center, Decatur, GA. These procedures were performed for polyps or malignancy. Real time PCR was used for analysis of NPY and catalase (antioxidant enzyme) expression.

**Primary enteric neuronal culture**

Primary enteric neuronal cultures were established from two-day-old WT and NPY−/− pups as described previously (16).

**Enzyme Linked Immunosorbent Assay (ELISA)**

Primary enteric neurons from WT and NPY−/− mice (129S-Npytm1Rpa/J, Stock no. 004545, Jackson Laboratory, Maine, US) were cultured as described previously (16). The colon from eight-week old WT and NPY−/− mice was harvested and cultured in RPMI medium for 24 h. TNF levels in the culture supernatants were determined by ELISA (Ray BioTech Inc, Norcross, GA).

**Immunostaining**

Colonic sections were immunostained with anti-NPY, anti-nNOS and anti-Peripherin antibodies (1:500, BD Laboratories) as described previously (16). The cleaved caspase-3
staining (1: 300) was expressed as a percentage of peripherin staining. The images were captured using a Zeiss fluorescence microscope, and analyzed by Metamorph (Molecular Devices, Silicon Valley, CA, USA) as described previously (17).

**Laser capture microdissection (LCM)**

Enteric ganglia were captured from cryo sections by LCM as described previously (17). The RNA was isolated from the ganglia using Arcturus Pico-Pure RNA Extraction Kit (Grand Island, NY) and amplified for NPY expression by real time PCR. GAPDH was used as loading control.

**Luciferase assay**

Enteric neurons were transfected with full length (−1078) and various deletion sequences of the NPY promoter (−278, −728, −867 and −1078 bp) in a pGL2-luciferase reporter system kindly provided by Dr. Denise Belsham (University of Toronto, Ontario, Canada) (18, 19). The cells were then stimulated with TNF (25 ng) for 6 h, and NPY promoter activity was determined by Dual Luciferase Assay Kit (Promega, Madison, WI), and expressed as Relative Luciferase Units (RLU) as compared to the empty pGL2 vector.

**Site-directed mutagenesis**

Site-directed mutagenesis was performed using the QuikChange Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The c-jun binding site (consensus sequence-5′-TGAGTC-3′) within the −769 NPY-Luc construct was mutated to generate mutant constructs Mut # 1 (CGATTCC) and Mut # 2 (GAAGCC). Primers were designed to amplify the mutated region (S. Table 1). The plasmid DNA of the −769 NPY-Luc construct was amplified with mutant primers and mutant clone plasmid DNA was isolated (Sigma Gen-Elute Midi prep Kit), and sequenced to confirm the mutation (Eurofins MWG Operon sequencing, Des Moines, IA).

**Chromatin immunoprecipitation (ChIP)**

ChIP assays were performed using manufacturer’s protocol (Upstate Biotechnology, Lake Placid, NY) using anti-c-Jun, anti-c-fos, anti-phospho-c-jun or anti-ATF (Cell Signaling) antibodies. For PCR, the primers: 5′-GGG AAG TGT TCT CAT CTA TG-3′ and antisense, 5′-GGC CAC TTCCA C AT TTA AA-3′ encompassing a 220 bp fragment (from −398 to −624 bp) of the mouse NPY promoter were used.

**Transcription Element Search System (TESS)**

The NPY promoter sequence (~2000 base pairs from the transcription start site of mouse NPY mRNA, NM_023456.2) was analyzed for putative transcription factor binding sites by TESS (http://www.cbil.upenn.edu/tess/).

**Transsepithelial electrical Resistance (TER)**

Caco2-BBE cells were seeded on transwell permeable filters (pore size 0.4 μm) at 40,000 cells/0.33 cm², (Corning, Lowell, MA). TER was measured using Millicel-ERS (Electrical Resistance System from Millipore, Billerica, MA) before and after basolateral addition of NPY (0.1 μM) at 1, 2, 24 and 48 h.
**Paracellular permeability**

FITC-dextran (4 kD) was added to the apical compartment of Caco2-BBE monolayer. At 0 and 24 h, 100 μl of the basolateral medium was sampled for FD4 translocation (mg of FITC-dextran release/ml) by measuring the absorbance (Excitation λ450 nm, Emission λ510 nm).

**Colonic permeability**

WT and NPY −/− mice were orally gavaged with FD-4 and colonic permeability was measured as described previously (20). The colonic muscle strips from WT and NPY −/− mice were tested ex vivo for FD-4 (22 mg/ml) permeability in an Ussing chamber (20). TER across the muscle strips was simultaneously monitored at 10, 20, 30, 45 and 60 min (T-10 to T-60).

**Western blotting**

Caco2-BBE/T84 monolayers on transwell permeable supports were exposed to NPY (0.1μM), and probed for claudins-1, 2 and 4 after 24 h (Life Technologies, 1: 2500), and pAkt after 1h (Cell Signaling, 1: 1000).

**Colonic motility assessment**

Colonic motility was evaluated by isometric muscle recording with electrical field stimulation as described previously (17). The longitudinal muscle strips with intact innervation were used for the experiment.

**Whole mount staining**

The myenteric plexus was peeled off from the formalin-fixed proximal colon, and was used for NADPH diaphorase staining. The neuronal numbers were counted using a 1mm² grid as described previously (16).

**Statistical analysis**

Data were analyzed using one-way ANOVA (Graph Pad Software, San Diego, CA), followed by Tukey’s multiple comparison tests, or Student’s t-test (two tailed unpaired) as applicable. A p value < 0.05 was considered statistically significant.

**Results**

**NPY knockdown is associated with attenuated TNF production**

Based on our previous observations that NPY knockdown mitigates experimental colitis (8), we investigated if NPY knockdown would modulate TNF production. We observed that primary enteric neuronal cultures from two-day-old WT mouse pups produced more TNF compared to NPY−/− pups (Figure 1A–B, p < 0.01). In addition, explant colon cultures from WT mice also produced more TNF compared to NPY−/− (Figure 1C, p< 0.05). We have previously demonstrated that NPY increases TNF production from enteric neuronal cells in vitro (8). Collectively our data suggests a cross talk between TNF-NPY in enteric neurons. To understand the relevance of this cross talk during inflammation, we next investigated whether TNF can directly activate NPY expression in enteric neurons.
TNF inhibitors attenuate NPY expression in enteric neurons, and TNF activates NPY promoter

Studies on primary cells and the enteric neuronal cell line developed in our laboratory (21) demonstrated that enteric neurons express both TNF receptors TNFR1 and TNFR2 (Supplemental Figure 1A), and TNF induced NPY expression in enteric neuronal cells (Figure 1D, p < 0.01). Further studies utilizing the neuronal cell line indicated that both TNF inhibitors etanercept (p < 0.05) and XPro1595 (Figure 1D, p < 0.01) inhibited NPY expression. These results indicate that NPY expression is inducible by TNF, suggestive of dynamic NPY-TNF cross-talk during inflammation in the ENS. We next assessed if TNF can regulate NPY promoter. We transiently transfected enteric neurons with pGL2-reporter plasmids containing various human NPY promoter deletion constructs as described in Methods. Luciferase assays demonstrated an increase in the reporter gene activity (2.5 ± 0.7, p < 0.05) in the region between −728 and −867 region upon TNF stimulation (Figure 1E). To investigate the downstream effectors of TNF signaling in enteric neurons, we analyzed the TNF-responsive region (−728 and −867 bp) for putative transcription factor binding sites utilizing the TESS database. Interestingly we found numerous putative binding sites for Activator Protein-1 (AP-1, includes c-jun, c-fos and Activating Transcription Factor, ATF), a well-known downstream effector of TNF, on NPY promoter. ChIP assays showed increased phospho-c-Jun binding to the −769bp region of the NPY promoter after TNF stimulation. Further, real-time PCR demonstrated a significant increase in the phospho-c-jun promoter occupancy (2.2 ± 0.5, p < 0.05, Figure 1F) in TNF-stimulated cells compared to control. To further ensure the requirement of phospho-c-jun binding in mediating TNF-induced promoter activity, mutations were introduced in the c-jun binding site (consensus sequence TGAGTCA) on NPY promoter. Our results indicate that mutations in the consensus sequence completely abolished the TNF-responsiveness, implying that phospho-c-jun binding is essential for TNF-induced NPY expression in enteric neurons (p< 0.01, Figure 1G). Collectively, these results support that TNF activates NPY promoter in enteric neurons.

NPY−/− mice display decreased intestinal permeability compared to WT

Increased epithelial permeability is a risk factor as well as a hallmark of IBD pathophysiology (22) and TNF has been demonstrated to increase epithelial permeability via claudin-2 (11). It has also been demonstrated that anti-TNF drugs can prevent epithelial barrier dysfunctions (23). Having established that NPY knockdown inhibits TNF production, we next investigated the relevance of this interaction in regulating epithelial permeability. We first compared the colonic paracellular permeability in WT and NPY−/− mice. We gavaged mice with FITC-Dextran (4 kD, FD-4) and serum levels of FD-4 (ng/gm serum protein) were measured after 4 h. We observed that serum FD-4 levels were lower in NPY−/− mice compared to WT, suggestive of decreased epithelial paracellular permeability in these mice (Figure 2A, p<0.05). We next performed ex vivo permeability studies on isolated distal colonic strips from WT and NPY−/− mice using an Ussing chamber. A significantly higher short circuit current (ISc) was observed in WT mice (12.39 ± 0.5 μA) compared to NPY−/− (3 ± 0.2μA, Figure 2B, p< 0.05), suggestive of increased permeability in WT mice. Further, reduced FD-4 flux was observed across the colonic muscle strips at 1 h.
in NPY−/− mice (90 ± 15 μg/cm², Figure 2C, p< 0.01) compared to WT mice (550 ± 165 μg/cm²). These data suggest that NPY may compromise the epithelial integrity.

**NPY increases permeability of the epithelial monolayer via pore-forming Claudin-2**

Having observed a difference in colonic permeability in mouse models and to define the mechanisms involved, we next assessed the effect of treatment with NPY (24) on colonic epithelial permeability *in vitro* (Caco2-BBE) using TER and macromolecular flux (FD-4). We observed a significant decrease in TER in NPY-treated cells compared to control in 24 h (54 ± 5.0 %, P < 0.01) and 48 h (45 ± 8%, p<0.001, Figure 2D), indicative of increased permeability. We observed increased flux of FD-4 in NPY-treated Caco2-BBE cells after 24 h (144.17 ± 12.58 μg/ml, p< 0.01) compared to untreated controls (34.92 ± 1.57 μg/ml, Figure 2E). Collectively, our *in vitro* and *in vivo* data indicate a central role of NPY in increasing epithelial permeability and subsequent susceptibility to inflammation. Given that NPY can increase permeability, we next investigated whether NPY could alter the expression of tight junction proteins in the epithelium. Among the tight junction proteins, claudin-2 has been associated with a “leaky” barrier and is up regulated in human IBD (25). Also it is reported that TNF induces claudin-2 in epithelia via PI3-K (11). Hence we assessed whether treatment with NPY affects claudin-2. We observed a modest increase in claudin-2 protein (2 ± 0.3, p< 0.05) after NPY treatment in Caco2-BBE cells (Figure 2F, p < 0.05). Further experiments revealed that effects of NPY were mediated in part by Akt activation (3.2 ± 0.1, p< 0.05, Figure 2F–G) as it was sensitive to inhibition by the phosphatidyl-inositol-3-kinase (PI3-K) inhibitor (LY 294002, LY). We also noticed that NPY induced similar Akt activation in T84 cells (Supplemental Figure 2A–B). We did not notice changes in other claudins like claudins- 1 and -4 on NPY treatment (Supplemental Figure C–D). Taken together our results indicate that in addition to mediating TNF effects, NPY can also have direct effects on permeability via PI3-K.

**TNF inhibitors attenuated NPY expression in enteric ganglia during experimental colitis**

Several studies have shown that TNF levels are upregulated in human IBD (10, 26). Having demonstrated TNF-regulation of NPY promoter *in vitro*, we next assessed if administration of TNF inhibitors can attenuate NPY expression during experimental colitis in mice. The *in vivo* study design utilizing a dextran sodium sulfate (DSS) model of colitis is represented in Figure 3A. We have previously demonstrated that NPY is upregulated in the colon during two experimental colitis models, and that NPY−/− mice are resistant to colitis (8). Now we observed that in the DSS colitis model, mice receiving intraperitoneal administration of TNF inhibitors exhibited attenuated NPY expression in the enteric ganglia as demonstrated by immunostaining and quantified by Metamorph (Figure 3B–C, p< 0.05). To further validate this finding, we isolated enteric ganglia by laser capture micro dissection and assessed NPY expression by real-time PCR. There was a 2 fold up regulation (± 0.1, p < 0.05) of NPY in the enteric ganglia of DSS-treated mice, which was significantly reduced by TNF inhibitors (Figure 3D, p <0.01). Further we observed that mice receiving the TNF inhibitors also exhibited less inflammation as assessed from loss of body weight (Figure 3E), colon length (Figure 3F) and histological damage (Figure 3G–H). In addition, we observed a difference in the anti-inflammatory effects of the two TNF inhibitors tested. Etanercept is a recombinant fusion protein that acts as a decoy receptor that binds TNF, thereby reducing its availability.
On the other hand, XPro1595 is a dominant negative inhibitor of TNF which depletes the TNF pool (composed of active TNF homotrimers) by replacing it with heterotrimers that do not bind to the receptor. A comparison of the inhibitors revealed that soluble TNF inhibition was more beneficial considering changes in colon length and (Figure 3E, p < 0.05) and histological damage (Figure 3G–H, p < 0.05).

**TNF inhibitors reduced oxidative stress and neuronal apoptosis in colitic mice, thereby improving neuronal survival**

Oxidative stress is a characteristic feature of IBD (27, 28) and inducible nitric oxide synthase (iNOS) expression is an established marker of inflammation and oxidative stress (29). We have previously demonstrated that NPY−/− mice exhibit less nitrosative stress and hence attenuated inflammation compared to WT. In this study we observed that NPY levels are upregulated in biopsies from IBD patients (Supplemental Figure 3A) and also there was increased oxidative stress in biopsies as evident from increased catalase expression (Supplemental Figure 3B). Analysis of oxidative stress markers revealed that XPro1595-treated mice had significant reduction in the expression of colonic iNOS as compared to DSS or DSS/etanercept-treated mice (Figure 4A, p < 0.05). We also observed an increase in the expression of the antioxidant enzyme catalase in DSS and DSS-etanercept treated mice, suggestive of increased oxidative stress (Figure 4B, p < 0.01). Since oxidative stress has been linked to increased neuronal apoptosis (30), we next investigated whether TNF inhibitors could attenuate apoptosis in the enteric ganglia (using cleaved caspase-3 immunostaining with peripherin as a general neuronal marker). We observed a significant reduction in apoptosis in colitic mice treated with TNF inhibitors as compared to DSS alone (p < 0.05, Figure 4C). A quantitative analysis of the immunostaining data is presented in Figure 4D. We next investigated whether a reduction in neuronal apoptosis would result in improved neuronal survival. We observed that the number of diaphorase (blue) and nNOS-positive (red) neurons in the myenteric plexi of mice treated with etanercept (p < 0.05) and XPro1595 (p < 0.001) were significantly higher when compared to DSS-treated mice (Figure 4E–G). Moreover we also observed that XPro1595 had more beneficial neuro-protective effects (neuronal survival, motility) compared to etanercept.

**TNF inhibitors improved colonic motility during experimental colitis**

Colonic motility dysfunctions are commonly associated with IBD (31–33). Also inducible nitric oxide (iNOS)- induced over production of nitric oxide has been implicated in the suppression of colonic contractility during IBD (29). Having demonstrated the protective role of TNF inhibitors against neuronal apoptosis, we next assessed if enhanced neuronal survival would improve colonic motility. We have previously demonstrated that WT mice exhibit severe colonic motility impairments during acute DSS colitis (8). We found that TNF inhibitors significantly improved neuronal relaxation responses (tetradotoxin-sensitive) from longitudinal muscle strips in mice. Non-adrenergic non-cholinergic (NANC) relaxation improved with etanercept treatment (22.57 ± 7.25 %), and was even better in XPro1595-treated mice (31.57 ± 6.34 %, p < 0.05, Figure 5A). The mice exposed to DSS alone (4.98 ± 2.0 %) exhibited significantly reduced relaxation due to extensive inflammation-induced neuronal loss. The representative tracings for relaxation are given in Figure 5B. Similarly we found that colonic contraction (induced after treatment of muscle strips with L-NAME,
nitric oxide inhibitor) improved in both etanercept and XPro1595-treated mice (p < 0.05, Figure 5C) as compared to mice on DSS alone. Representative tracings for contraction are given in Figure 5D. Colonic motility is coordinated by complex neuron-smooth muscle interactions; hence we also investigated the relaxation and contraction responses of the colonic smooth muscle. We found that smooth muscle relaxation (induced by sodium nitroprusside, SNP) significantly improved in TNF-inhibitor treated mice as compared to the DSS-treated mice (p < 0.05, Figure 5E). However, smooth muscle contraction responses significantly improved only in XPro1595-treated mice (p < 0.05, Figure 5F). The representative tracings are given in Figure 5G. These data suggest that inhibition of sTNF with XPro1595 improved both neuronal and smooth muscle responses that ultimately coordinate colonic motility. In aggregate, our findings indicate that TNF inhibitors decreased oxidative stress and improved neuronal survival, which in turn, improved the colonic motility, during experimental colitis in mice.

**Discussion**

The role of neuro-immune interactions has gained significant attention in the pathogenesis of inflammatory diseases such as IBD (34, 35). Our current study reveals a whole new perspective on the role of NPY during inflammation as represented in Figure 6. We have demonstrated previously that NPY is up regulated during experimental colitis, and NPY knockout mice exhibit less inflammation using two models of experimental colitis (8). In the present study we demonstrate that primary enteric neuronal cells from NPY<−/−> mice produce less TNF than WT mice. This finding suggests a strong cross talk between NPY-TNF in the enteric neurons. We have also demonstrated previously that NPY co-localizes with neuronal nitric oxide synthase containing neurons (nNOS) (16). We identified that up regulation of NPY during inflammation also involves nNOS upregulation, leading to increased levels of nitric oxide and oxidative stress via creation of a double knockout mice for NPY<−/−>/nNOS<−/−> (8). Since nNOS–derived nitric oxide also regulates colonic motility under normal conditions, decreased nNOS in NPY<−/−> mice accounts for reduced colonic relaxation in these mice. Collectively, these observations indicate that NPY can regulate TNF production, oxidative stress and colonic motility. However the trigger for NPY up regulation during inflammation was unclear.

TNF is a key pro-inflammatory cytokine in IBD and increased expression of TNF has been reported in the colonic biopsies from IBD patients (10). In addition, TNF is the popular drug target in IBD. Hence we investigated if increased TNF levels during inflammation could up regulate NPY expression. In vitro studies demonstrated that TNF induces NPY expression in enteric neuronal cell lines and primary enteric neuronal cultures. Further we validated that TNF-induced NPY expression is highly sensitive to inhibition by TNF inhibitors. Further studies revealed that TNF regulates NPY promoter in enteric neurons via c-jun phosphorylation. This is important as c-jun expression is highly induced in response to neuronal injury and c-jun activation is reported to up regulate the expression of neuropeptides such as vasoactive intestinal peptide (VIP) and NPY in the dorsal root ganglia (36, 37). This finding suggests that NPY in enteric neurons is inducible by TNF during inflammation, and NPY neurons are an immediate sensor of upregulated TNF signaling.
The breach of epithelial barrier is a critical event that precedes inflammation and is implicated in the pathogenesis of IBD (38). A leaky barrier leads to increased exposure of the mucosal immune systems to pro-inflammatory molecules like TNF, and bacterial antigens adding to the severity of inflammation (39). In addition, pro-inflammatory cytokines like TNF can induce barrier dysfunctions via disrupting tight junctions (11). Having established that NPY knockdown inhibits TNF production, we next investigated the relevance of NPY-TNF cross talk in regulating epithelial permeability. This is important because NPY-producing sub mucosal neurons are in close proximity with the epithelium and under normal conditions NPY is an anti-secretory peptide (24, 40, 41). However studies have shown that anti-secretory effects of NPY are subjugated during inflammation as demonstrated (6, 42). We demonstrate that NPY−/− mice had improved barrier functions compared to WT mice, which might have reduced their susceptibility to inflammation as reported by us previously (8). We also observed that NPY increased the permeability of Caco2-BBE cells in vitro as demonstrated by a decrease in TER, which may be the result of alterations in tight junction size or ion selectivity. A further study revealed that like TNF, NPY also up regulates claudin-2, a pore-forming tight junction protein, in Caco2-BBE cells in vitro. Thus our data suggest that NPY-induced claudin-2 may be one of the contributing factors to enhanced epithelial permeability, and may involve other tight junction proteins.

TNF can regulate neuronal apoptosis via oxidative stress (43) and is a major cause of autonomic dysfunction during diseases (13). We have previously demonstrated that inflammation damages the enteric neurons resulting in chronic colonic motility impairments in mouse models of colitis (8). In the current study, we demonstrate that TNF-induced oxidative stress results in enteric neuronal apoptosis that contributes to motility defects post inflammation. Accordingly we identified that enteric neurons from mice receiving TNF inhibitors had significantly reduced oxidative stress and neuronal apoptosis leading to enhanced neuronal survival and significant improvements in colonic motility. Further, a comparison between the two TNF inhibitors revealed that selective inhibition of soluble TNF by XPro1595 resulted in a significant reduction of inflammation as demonstrated by reduction in colon length, oxidative stress and histological damage. Studies utilizing mouse models of inflammatory diseases have demonstrated that selective inhibition of soluble TNF is beneficial since sparing of transmembrane TNF preserves the innate immune functions (44). Similar beneficial results in neuronal survival with soluble TNF inhibition have also been demonstrated in the CNS in diseases like Alzheimer’s (45–47).

Despite being a pro-inflammatory cytokine, TNF has been identified to regulate enteric neuronal development in vitro (48). Also, TNF can regulate neuronal apoptosis via oxidative stress (43). Similarly, we and others have shown that NPY has neurotrophic effects (16, 49, 50). However despite their protective roles under normal conditions, we demonstrate that during inflammation TNF up regulation induces NPY, and TNF-NPY cross talk aggravates inflammatory signaling, induces barrier dysfunctions and colonic motility impairments. Our data highlights the significant role of NPY-producing neurons in the ENS as a mediator of the TNF effects. Further, NPY-producing neurons in the ENS are immediate targets and sensors of pro-inflammatory TNF signals. Our results suggest that NPY antagonists might also offer some therapeutic benefits in the treatment of IBD by preventing the propagation...
of TNF signals. We also suggest that selective inhibition of soluble TNF may be a more efficacious approach compared to non-selective blockade with etanercept or other anti-TNF biological therapies.

**Supplementary Material**

Refer to Web version on PubMed Central for supplementary material.

**Acknowledgments**

**Funding** This work is funded by the Crohn's and Colitis Foundation of America Career Development Award (BC), NIH-RO1 (DK080684, SS), VA-MERIT award (SS) and DDRDC (DK064399, SS), DK06411 (SVS), DK59888 (AN) and DK080058 (EK)

**Abbreviations used in this paper**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSS</td>
<td>dextran sodium sulfate</td>
</tr>
<tr>
<td>ENS</td>
<td>enteric nervous system</td>
</tr>
<tr>
<td>ELISA</td>
<td>enzyme-linked immunosorbent assay</td>
</tr>
<tr>
<td>FD-4</td>
<td>FITC-dextran-4</td>
</tr>
<tr>
<td>LY</td>
<td>LY-294002</td>
</tr>
<tr>
<td>NPY</td>
<td>neuropeptide Y</td>
</tr>
<tr>
<td>nNOS</td>
<td>neuronal nitric oxide synthase</td>
</tr>
<tr>
<td>PD</td>
<td>PD-98059</td>
</tr>
<tr>
<td>TER</td>
<td>transepithelial resistance</td>
</tr>
<tr>
<td>TNF</td>
<td>tumor necrosis factor alpha</td>
</tr>
</tbody>
</table>

**References**


*Inflamm Bowel Dis. Author manuscript; available in PMC 2014 November 01.*


42. Klompus M, Ho W, Sharkey KA, McKay DM. Antisecretory effects of neuropeptide Y in the mouse colon are region-specific and are lost in DSS-induced colitis. Regul Pept. 2010
47. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate...


Figure 1. NPY knockdown reduces TNF production from enteric neurons, and TNF activates NPY promoter

Primary enteric neuronal cultures from two-day-old WT and NPY\textsuperscript{−/−} mice pups were cultured for 10 days at 37°C. Colonic explants from eight-week-old WT and NPY\textsuperscript{−/−} mice were cultured in RPMI for 24 h. The supernatants from primary cultures and colon explants were assayed for TNF release by ELISA. Enteric neuronal cell lines were stimulated with TNF (25 ng) in presence or absence of TNF inhibitors (25 ng). RNA was extracted after 6 h and amplified for NPY expression by real-time PCR. Enteric neuronal cell line was transfected with various NPY deletion promoter constructs and assayed for luciferase activity in presence and absence of TNF. The chromatin from enteric neuronal cells treated with/without TNF was immunoprecipitated with phospho-c-jun antibody. Fold change in c-jun binding on NPY promoter was assessed by real-time PCR. The site directed mutagenesis of c-jun binding site was performed using a kit as detailed in methods, and TNF-induced promoter activity was monitored by luciferase assay in two mutant clones (Mut #1 & #2).

(A) Primary enteric neurons in culture under light microscope (20X) (B) TNF levels in WT and NPY\textsuperscript{−/−} enteric neurons (C) TNF levels in colon explants cultures from WT and NPY\textsuperscript{−/−} mice (D) NPY expression in enteric neuronal cells treated with TNF and TNF inhibitors (E) luciferase assay depicting activation of NPY promoter constructs by TNF (F) Fold change in...
phospho-c-jun expression with TNF and luciferase assay utilizing mutated constructs of c-jun binding site. Values are Mean ± SEM, n = 6, * p < 0.05, ** p < 0.01.
Figure 2. NPY increases permeability of colonic epithelial monolayer via pore-forming claudin-2

(A) WT and NPY −/− mice were gavaged with FITC Dextran (FD4, 4 kD) and amount of FD4 released into the serum (ng/gm serum protein) was measured after 4 h in a spectrofluorimeter (excitation λ 450 nm, emission λ 510 nm). The colonic muscle strips from WT and NPY −/− mice were tested *ex vivo* in Ussing chamber for (B) short circuit current, ISc (μA) and (C) FD-4 (22mg/ml) translocation over a time period of 0–60 min as described in Methods. (D) Caco2-BBE cells on transwell supports were treated with NPY (0.1 μM) and TER measured at 1, 2, 24 and 48h. (E) Caco2-BBE cells were treated with NPY and the translocation of apically added FD-4 into the basolateral medium was measured after 24 h relative to control. (F) Caco2-BBE cells were cultured on transwell filter supports and treated with NPY (0.1 μM) in presence or absence of PI3-K inhibitor (LY-294002) and cell lysates were analyzed for claudin-2, pAKt and Akt by Western blotting. Results are graphically represented in (G). Values are Mean ± SEM, n = 6, * p < 0.05, **p< 0.01, *** p< 0.001.
Figure 3. TNF inhibitors attenuate enteric neuronal NPY expression and inflammation in murine experimental colitis

Mice were given DSS in drinking water for seven days, with three intraperitoneal injections of either etanercept or XPro1595 at 10 mg/kg body weight starting from day 1 as outlined in (A). On day 8, mice were euthanized and colon was collected. The paraffin-embedded colon sections were assessed for (B) NPY expression (red) by immunostaining using peripherin (green) as general neuronal marker, and the staining intensity arbitrarily quantified by Metamorph is graphically represented in (C). The colonic ganglia were isolated by LCM from cryo sections, and NPY expression was assessed by real-time PCR in (D). Markers of inflammation like (E) Body weight loss (F) Colon length (cm) and Histological damage (G–H) after hematoxylin-eosin staining were also determined in mice receiving DSS alone or
both DSS and TNF inhibitors. Values are Mean ± SEM, n = 6, * p < 0.05, ** p < 0.01.
Magnification 20 X, Scale bar 50 μm.
Figure 4. TNF inhibitors reduce enteric neuronal apoptosis and enhance neuronal survival via attenuation of oxidative stress.
Mice were administered DSS in drinking water for seven days; they also received three intraperitoneal injections (every third day) of either etanercept or XPro1595 at 10 mg/kg body weight. Oxidative stress was evaluated from inducible nitric oxide synthase (iNOS) and antioxidant catalase expression in mouse colonic mucosa by real time PCR. Paraffin-embedded colonic sections were immuno stained for cleaved caspase-3, and peripherin was used as a general neuronal marker. Intensity of staining was assessed by Metamorph. Myenteric plexi peeled from the formalin-fixed colonic tissues of mice were stained for diaphorase and neuronal nitric oxide synthase (nNOS) positive neurons as described in Methods (A) iNOS, and (B) catalase expression. (C) Representative images of cleaved caspase-3 (red) staining in colonic sections, ganglia are represented by arrows, and graphical representation of staining intensity as quantified by Metamorph in (D). Representative images of diaphorase (blue) and nNOS staining (red) is represented in (E) and neuronal counts are represented in (F) and (G). Values are Mean ± SEM, n = 6, * p < 0.05, *** p< 0.001. Magnification 20X, Scale bar 50 μm.
Figure 5. Administration of TNF inhibitors improves colonic motility in mice with colitis
Mice were given DSS in drinking water for seven days, with three intraperitoneal injections of either etanercept or XPro1595 at 10 mg/kg body weight starting from day 1. On day 8, mice were euthanized and the longitudinal muscle strips peeled from the colon were subjected to isometric muscle recording (as detailed in Methods) with electrical field stimulation for assessment of neuronally-mediated colonic relaxation and contraction. In addition, these muscle strips were stimulated with carbachol to assess smooth muscle contraction, and with sodium nitroprusside (SNP) to evaluate smooth muscle relaxation responses. (A) Neuronally mediated relaxation, the representative tracings are given in (B). Colonic contraction responses in mice are plotted in (C), the representative tracings are shown in (D). Smooth muscle relaxation and contraction responses are given in (E) and (F) respectively, with the tracings represented in (G). Values are Mean ± SEM, n = 6, * p < 0.05, **p < 0.01, *** p < 0.001.
Figure 6. Modeling TNF-NPY interactions

Proposed scheme depicting how TNF-NPY cross talk regulates inflammation, epithelial permeability and colonic motility. The possible mechanism of regulation of these effects by TNF-inhibitors is also indicated. The enteric neurons express both the TNF receptors (TNFR1 and TNFR2). XPro1595 inhibits trimerization of soluble TNF and its interaction with TNFR1, whereas etanercept inhibits transmembrane TNF actions through TNFR1 and TNFR2. TNF mediated effects are represented by red arrows and NPY induced effects are shown by purple arrows. TNF induces NPY expression in the ENS, and vice versa. NPY up regulation can have downstream effects of increasing epithelial permeability through phosphatidyl-inositol-3-kinase (PI3-K)-induced claudin-2 up regulation. Inflammation-induced oxidative stress in the enteric neurons leads to enteric neuronal apoptosis and impairments in colonic motility. Both TNF inhibitors attenuate NPY expression, oxidative stress and enteric neuronal apoptosis, thereby enhancing neuronal survival and improving colonic motility.